Journal Article

(–)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice

Junko Mimoto, Katsuyuki Kiura, Keisuke Matsuo, Tadashi Yoshino, Ichiro Takata, Hiroshi Ueoka, Mikio Kataoka and Mine Harada

in Carcinogenesis

Volume 21, issue 5, pages 915-919
Published in print May 2000 | ISSN: 0143-3334
Published online May 2000 | e-ISSN: 1460-2180 | DOI:
(–)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics


Show Summary Details


Risks of secondary lung cancer in patients with non-small cell lung cancer and small cell lung cancer are estimated to be 1–2% and 2–10% per patient per year, respectively. Cisplatin is widely used in the treatment of lung cancer and is also known as a carcinogen in experimental animals. In this study, the effect of (–)-epigallocatechin gallate (EGCG) on cisplatin-induced lung tumors in A/J mice was investigated. Female A/J mice (4 weeks old) were divided into four groups: group 1, control without treatment; group 2, EGCG treatment (1 mg/ml in tap water); group 3, weekly cisplatin treatment (1.62 mg/kg body wt, i.p.) for 10 weeks; group 4, cisplatin plus EGCG treatment (EGCG was started 2 weeks before cisplatin treatment). Four groups of mice were killed at week 30 after treatment. Tumor incidence was 26.3% (5/19) in group 1, 30% (6/20) in group 2, 100% (19/19) in group 3 and 94.4% (17/18) in group 4. Tumor multiplicity (the number of tumors per mouse, mean ± sd) was 0.4 ± 0.8 in group 1, 0.4 ± 0.8 in group 2, 5.1 ± 2.1 in group 3 and 2.8 ± 2.3 in group 4. Tumor multiplicity was significantly reduced by adding EGCG to cisplatin-treated mice (P < 0.01). Furthermore, EGCG significantly reduced cisplatin-induced weight loss from 24.7–26.3% (cisplatin treatment) to 10.8–11.6% (cisplatin plus EGCG treatment) (P < 0.01). These findings suggest that EGCG can inhibit cisplatin-induced weight loss and lung tumorigenesis in A/J mice.

Keywords: EGCG, (–)-epigallocatechin gallate; JCRB, Japanese Cancer Research Resources Bank; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.

Journal Article.  3522 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.